PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the safety of using PSMA-PET/mpMRI to define
radiotherapy targets, while meeting all current planning criteria. This study also intends to
determine the feasibility of performing stereotactic body radiation therapy with simultaneous
integrated boost on the dominant intra-prostatic lesions while meeting all current planning
criteria.